The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the

7 Best Strong Buy European Stocks to Invest In. On April 2, 2026, ABIVAX Société Anonyme (NASDAQ:ABVX) appointed Michael Nesrallah as chief commercial officer. Michael Nesrallah will lead global commercial strategy and launch preparation for obefazimod as the company moves toward potential regulatory approval, bringing more than 20 years of biopharmaceutical experience, including prior senior leadership roles at Takeda.

On March 24, 2026, Barclays raised the price target on ABIVAX Société Anonyme (NASDAQ:ABVX) to $148 from $142 and maintained an Overweight rating. Barclays said a “clean” Data and Safety Monitoring Board review supports continued ABTECT maintenance, with a readout expected in late Q2.

Photo by RephiLe water on Unsplash

On March 15, 2026, Jefferies initiated coverage on ABIVAX Société Anonyme (NASDAQ:ABVX) with a Buy rating and a $160 price target. Jefferies described obefazimod as a “differentiated” treatment for ulcerative colitis and said the upcoming Q2 maintenance readout appears “fairly de-risked,” while also pointing to potential in Crohn’s disease.

ABIVAX Société Anonyme (NASDAQ:ABVX) develops therapeutics targeting chronic inflammatory diseases.

While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.